Physiogenex is a renowned preclinical contract research organization (CRO) specializing in metabolic and cardiovascular diseases.
In this focused niche market we provide integrated preclinical and scientific consultancy services to optimize drug discovery development and shorten the time to market for new targets and compounds. Our in-house capabilities and innovative customized solutions, combined with our scientific team expertise, provide our partners with reliable and long-lasting R&D collaborations.
We offer the following services:
- Discovery: Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision
- Preclinical development: In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs
- Marketing: Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning
Physiogenex pioneers the development of radiolabeled tracer-based kinetic methods and predictive animal nutritional models. We thus provide our partners with pertinent and reliable discovery and preclinical data for successful strategic decision-making. Physiogenex has rapidly achieved global player status by virtue of its unique expertise, covering complex metabolic disorders associated with diabetes, obesity, lipid disorders (dyslipidemia, hypercholesterolemia) and liver disorders (NASH / NAFLD), hypertension and cardiovascular diseases.
Physiogenex is an entrepreneurial, science-driven company dedicated to helping pharmaceutical, biotechnology and nutraceutical companies.